ArticleRevista da Associacao Medica Brasileira (1992)2026
The predictive value of Hemoglobin-Albumin-Lymphocyte-Platelet score for maximal cytoreduction surgery in advanced-stage epithelial ovarian cancer.
Article in Revista da Associacao Medica Brasileira (1992), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveThe Hemoglobin-Albumin-Lymphocyte-Platelet score has shown prognostic value across various cancers; however, its utility in predicting cytoreductive outcomes in advanced epithelial ovarian cancer remains unclear. The aim of this study was to determine whether the preoperative Hemoglobin-Albumin-Lymphocyte-Platelet score predicts maximal cytoreduction at primary cytoreductive surgery.
methodsIn this single-center study, we analyzed data from 140 patients with epithelial ovarian cancer who underwent primary cytoreductive surgery at our clinic. Patients were categorized by residual disease: maximal cytoreduction (no macroscopic residual disease, n=104), optimal cytoreduction (n=19), and suboptimal cytoreduction (n=17). Preoperative Hemoglobin-Albumin-Lymphocyte-Platelet, CA-125, and clinical variables were compared across groups. Discrimination for maximal cytoreduction was assessed using receiver operating characteristic analysis.
resultsThe maximal cytoreduction group had higher preoperative hemoglobin and lymphocyte counts, lower platelet counts, and lower CA-125 levels (p<0.005). Median Hemoglobin-Albumin-Lymphocyte-Platelet was significantly higher in maximal cytoreduction vs. optimal cytoreduction vs. suboptimal cytoreduction (35.37 vs. 21.10 vs. 20.19; all p<0.001). For predicting maximal cytoreduction, the Hemoglobin-Albumin-Lymphocyte-Platelet cutoff of 24.96 yielded a sensitivity of 71.4% and a specificity of 71.4% (area under the curve: 0.792; p<0.001). A CA-125 cutoff of 260.50 IU/mL provided a sensitivity of 71.4% and a specificity of 65.7% (area under the curve: 0.758; p<0.001).
conclusionThe preoperative Hemoglobin-Albumin-Lymphocyte-Platelet score demonstrates good discrimination for predicting maximal cytoreduction in advanced epithelial ovarian cancer and appears to perform at least comparably to CA-125. Given that patients selected for neoadjuvant chemotherapy were excluded, these performance estimates apply to a surgically selected population. Given its low cost and universal availability, Hemoglobin-Albumin-Lymphocyte-Platelet may support preoperative selection and counseling before cytoreductive surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.